Last updated on June 2008

Atorvastatin for the Treatment of Retinal Vein Occlusion

Brief description of study

The ATORVO study is designed to determine whether atorvastatin (Lipitor) can improve vision, when compared to placebo

Detailed Study Description

Retinal vein occlusion (RVO), a common cause of visual loss in the Western world, is a disease whose etiology resembles that of classic atherosclerosis. A therapy that lowers the risk of arterial and venous thrombosis would seem to be a reasonable approach to managing this disease, for which there is currently no treatment. ATORVO is a randomized double-masked clinical trial comparing a daily dose of 80 mg of atorvastatin to matched placebo in persons recently diagnosed with RVO. At 24 weeks after randomization, we will evaluate each participant's visual acuity and the presence of secondary complications related to RVO.

Clinical Study Identifier: NCT00517257

Contact Investigators or Research Sites near you

Start Over

David T Wong, MD

St. Michael's Hospital
Toronto, ON Canada
  Connect »